Laboratory Tests for Heart Failure Diagnosis and Management

Core Laboratory Tests for Initial Diagnosis

The American Heart Association recommends complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, fasting blood glucose, lipid profile, liver function tests, iron studies, and thyroid-stimulating hormone as initial laboratory evaluation for patients presenting with heart failure 1
Complete blood count is used to identify anemia which can exacerbate or mimic heart failure symptoms, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Urinalysis is used to detect proteinuria or other renal abnormalities that may contribute to fluid retention, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Serum electrolytes, including calcium and magnesium, are used to identify electrolyte imbalances that may affect cardiac function or be caused by diuretic therapy, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Blood urea nitrogen and serum creatinine are used to assess renal function, which is crucial for management decisions and prognosis, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Fasting blood glucose is used to identify diabetes, which is both a risk factor and comorbidity in heart failure, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 3
Lipid profile is used to assess cardiovascular risk factors, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Liver function tests are used to evaluate hepatic congestion and assess for underlying liver disease, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Thyroid-stimulating hormone is used to rule out thyroid disorders that can cause or exacerbate heart failure, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Iron studies, including serum iron, ferritin, and transferrin saturation, are used to identify iron deficiency, which is common in heart failure and impacts symptoms and outcomes, as recommended by the American Heart Association 1

Biomarkers for Diagnosis and Risk Stratification

B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurements are essential for supporting or excluding the diagnosis of heart failure, risk stratification, establishing prognosis, and monitoring disease progression and response to therapy, as recommended by the American Heart Association 1, 4
BNP or NT-proBNP levels should be measured at initial presentation, hospital admission, and prior to discharge, as recommended by the American Heart Association 1
Cardiac troponin levels may be useful for determining prognosis or disease severity in hospitalized patients with acute decompensated heart failure and identifying potential ischemic etiology, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 4

Additional Testing Based on Clinical Suspicion

Screening for hemochromatosis should be performed when iron overload is suspected, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 3
HIV testing should be performed in patients with risk factors or unexplained cardiomyopathy, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 3
Diagnostic tests for rheumatologic diseases should be performed when clinical suspicion exists, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 3
Testing for amyloidosis should be performed in patients with unexplained heart failure with preserved ejection fraction, particularly older patients, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 3

Serial Laboratory Monitoring

Renal function and electrolytes should be monitored regularly, especially after initiation or dose adjustment of diuretics, ACE inhibitors, ARBs, or aldosterone antagonists, during episodes of acute illness, and in patients with severe heart failure requiring frequent medication adjustments, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1

Non-Laboratory Diagnostic Tests

A 12-lead electrocardiogram is required for all patients with suspected heart failure, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Chest radiography (PA and lateral) should be performed to assess heart size and pulmonary congestion, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 1
Two-dimensional echocardiography with Doppler should be performed to assess left ventricular ejection fraction, size, wall thickness, and valve function, as recommended by the American Academy of Family Physicians and the American Heart Association 2, 3

Pitfalls and Caveats

BNP and NT-proBNP levels can be elevated in conditions other than heart failure, including advanced age, renal dysfunction, atrial fibrillation, pulmonary hypertension, and acute pulmonary embolism, as noted by the American Academy of Family Physicians and the American Heart Association 2, 4, 1
BNP and NT-proBNP levels may be falsely low in obesity, flash pulmonary edema, and HFpEF, as noted by the American Heart Association and the American Academy of Family Physicians 3, 2, 1
Laboratory abnormalities that may complicate heart failure management include hyponatremia, worsening renal function, and hyperkalemia, as noted by the American Academy of Family Physicians and the American Heart Association 2, 1

Diagnostic Approach for Chronic Heart Failure

Initial Screening

The European Society of Cardiology recommends an electrocardiogram (ECG) as the initial test to screen for chronic heart failure, as a normal ECG has a negative predictive value exceeding 90% to exclude left ventricular systolic dysfunction, making heart failure unlikely 5, 6, 7, 8
A completely normal ECG suggests the diagnosis of chronic heart failure should be carefully reviewed, as heart failure (especially due to LV systolic dysfunction) is unlikely 5, 6, 9, 7
The negative predictive value of a normal ECG to exclude LV systolic dysfunction exceeds 90% 5, 6, 7, 8

Diagnostic Algorithm

An ECG should be obtained first in all patients with suspected chronic heart failure, followed by natriuretic peptide testing if the ECG is abnormal or clinical suspicion remains high 5, 6, 9, 7, 8
Natriuretic peptides are most useful as a "rule out" test due to their consistently high negative predictive values 5, 6, 7, 8
A low-normal concentration in an untreated patient makes heart failure unlikely as the cause of symptoms 9

Definitive Diagnosis

Echocardiography is required to confirm the diagnosis, as objective evidence of cardiac dysfunction at rest is necessary 5, 6, 7, 8
The most important parameter is the LV ejection fraction for distinguishing systolic dysfunction from preserved systolic function 5, 6, 7, 8
Echo provides assessment of valvular function, cardiac filling characteristics through Doppler, and helps determine etiology 5, 6, 7, 8

Critical Considerations

The American Heart Association and European Society of Cardiology emphasize the importance of not skipping the ECG, as an abnormal ECG has poor specificity but a normal ECG has excellent negative predictive value 5, 6, 9, 7
Clinical presentation, ECG abnormality, and objective cardiac dysfunction on imaging form the diagnostic triad for chronic heart failure 5, 6, 7

Essential Laboratory Evaluation for Newly Diagnosed Congestive Heart Failure

Initial Laboratory Panel (Class I Recommendation – ESC)

For every adult with newly diagnosed CHF, obtain a comprehensive baseline panel that includes hemoglobin and white‑cell count, serum sodium and potassium, urea and creatinine with estimated GFR, liver enzymes (bilirubin, AST, ALT, GGT), fasting glucose, HbA1c, thyroid‑stimulating hormone, and iron studies (ferritin and transferrin‑saturation/TIBC) to identify comorbidities and guide therapy. 10, 11, 12, 13
Hemoglobin and white‑cell count help detect anemia, a condition that can mimic or worsen HF symptoms and independently worsens prognosis. (Class I) 10
Serum creatinine/eGFR and BUN provide essential information for dosing ACE inhibitors, ARBs, and diuretics, offer prognostic insight, and enable early detection of cardiorenal syndrome. (Class I) 10
Sodium and potassium measurements are required to monitor diuretic response and to identify electrolyte disturbances that directly affect cardiac contractility and arrhythmia risk. (Class I) 10
Liver function tests reveal hepatic congestion secondary to right‑sided HF and inform the safe use of hepatically metabolized drugs such as amiodarone and warfarin. (Class I) 10, 14
Glucose and HbA1c identify diabetes, a major HF risk factor and comorbidity that must be managed concurrently. (Class I) 10
TSH screening uncovers thyroid dysfunction, a reversible cause of HF that is frequently missed without testing. (Class I) 10
Iron studies detect iron deficiency, which is common in HF and worsens symptoms and outcomes even when anemia is absent; treatment improves functional status. (Class I) 10, 11, 13

Natriuretic Peptide Testing (Class IIa Recommendation – ESC)

Measure BNP or NT‑proBNP at the initial assessment (including at hospital admission and before discharge) to support diagnosis, stratify risk, and estimate prognosis. (Class IIa) 10, 11

Frequency of Biochemical Monitoring (Class IIa Recommendation – ESC)

Re‑check renal function and electrolytes after starting or adjusting doses of diuretics, ACE inhibitors, ARBs, or aldosterone antagonists. (Class IIa) 14
Repeat these tests during acute illnesses that cause fluid‑electrolyte losses (e.g., vomiting or diarrhea). (Class IIa) 14
Perform additional monitoring when non‑steroidal anti‑inflammatory drugs are introduced or diuretic doses are changed. (Class IIa) 14
The 2016 ESC guidelines stress that biochemical monitoring is especially critical during up‑titration of renin‑angiotensin system blockers and in the setting of intercurrent illnesses. (Class IIa) 14

Essential Non‑Laboratory Tests (Class I Recommendation – ESC)

A 12‑lead ECG is mandatory for all CHF patients to define rhythm, rate, QRS morphology/duration, and to guide decisions regarding device therapy. (Class I) 10, 11
Chest radiography should be obtained to rule out alternative pulmonary pathology and to identify pulmonary congestion, particularly in acute presentations. (Class I) 10, 11